Indegene Limited
Book Built Issue IPO · NSE, BSE
- Price band
- ₹430 - ₹452
- Lot size
- 33 shares
- Issue amount
- ₹1,841.76 cr
- Total subscription
- 70.26×
- Opens
- 6 May 2024
- Closes
- 8 May 2024
- Allotment
- 10 May 2024
- Listing
- 13 May 2024
Offer at a glance
Issue overview
- Issue size
- 4,07,46,891 shares
- Face value
- ₹2 per share
- Minimum investment
- ₹14,190
- Fresh issue
- ₹760 cr
- Offer for sale
- ₹1,081.76 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,916
- Issue type
- Book Built Issue IPO
- Shares before issue
- 22,24,35,091
- Shares after issue
- 23,92,49,250
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 33 | ₹14,916 |
| sHNI | 14 | 462 | ₹2,08,824 |
| bHNI | 68 | 2,244 | ₹10,14,288 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs(10L +) | 8,760 | 1,08,020 |
| HNIs (2-10L) | 4,380 | 1,78,974 |
| RETAIL | 4,29,231 | 24,93,188 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 365.85 | 70,505.94 |
| RETAIL | 640.24 | 4,991.06 |
| HNIs 2+ | 91.46 | 3,937.7 |
| HNIs 10+ | 182.93 | 11,384.28 |
| EMPLOYEES | 13.39 | 88.13 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Dec-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| EPS | 10.84 | 11.97 | 7.46 |
| ROE | 0 | 0 | 0 |
| ROCE | 0 | 0 | 0 |
| RONW | 18.23 | 25.02 | 21.57 |
| PRE IPO(PE) | 7.55 | 0 | 0 |
| POST IPO(PE) | 37.78 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Founded in 1998, Indegene Limited is a leading digital solutions provider for the life sciences industry, helping companies with everything from drug development and clinical trials to regulatory submissions and sales & marketing. The company offers a wide range of services through its Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions, along with expert consultancy. Its subsidiary, DT Consulting, specializes in guiding life sciences firms through digital transformation to enhance customer experiences. Indegene has also been recognized for its workplace excellence, winning the Platinum Level award at the 2023 Healthy Workplace Conference and Awards. With a global team of 5,181 professionals and 65 active clients across India, North America, Europe, China, and beyond, Indegene continues to deliver innovative and impactful solutions for the life sciences sector.
Strengths
- Deep Healthcare Industry Expertise: A large portion of the team has healthcare backgrounds, enabling the company to understand sector-specific challenges and deliver tailored, effective solutions.
- Use of Advanced Digital Technologies: Employs AI, machine learning, and advanced analytics to automate processes, boost efficiency, and provide innovative, high-value solutions for clients.
- Strong Trust Among Leading Biopharma Companies: Delivers high-quality services that have helped build long-term relationships with major biopharma clients, including the top 20 by revenue, demonstrating reliability and adaptability to evolving industry needs.
Risk factors
- Influence of Industry Shifts: Operating within the life sciences sector makes the company sensitive to changing regulations, evolving healthcare policies, and rapid technological advancements. Slower industry growth or rising competition could impact its revenue and profitability.
- Complex Revenue Structures: The company’s business model and revenue streams may be difficult for investors to interpret, potentially causing hesitation and affecting its ability to raise capital for future expansion.
Promoters
BCP Topco VII Pte. Ltd
Registrar & documents
Lead manager
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory, Securities (India) Private Limited, Securities (India) Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
Aspen Block G4, 3 rd Floor, Manyata EmbassyBusiness Park, Outer Ring Road, Nagawara Bengaluru 560 045
+91 80 4674 4567
[email protected]Company website ↗Frequently Asked Questions
What is Indegene IPO GMP today?
As of today, Indegene IPO Grey Market Premium (GMP) is reported at +₹275 per share. Based on the upper price band of ₹452, the estimated listing price is ₹727 (+60.8% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Indegene IPO?
The minimum bid lot size for Indegene IPO is 33 shares. At the cut-off price of ₹452 per share, retail investors need a minimum application amount of ₹14,916 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).
When will Indegene IPO allotment status be announced?
The allotment status for Indegene IPO is scheduled to be finalized on 10 May 2024. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Link Intime India Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Indegene IPO allotment status online by PAN?
To check Indegene IPO allotment status: 1) Visit the registrar portal (Link Intime India Private Limited) or the BSE IPO allotment page. 2) Select 'Indegene Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.